Allogene Therapeutics, Inc. (ALLO) Shareholders’ equity 2019–2025
Allogene Therapeutics, Inc. (ALLO) shareholders’ equity at each fiscal year-end, per SEC filings.
$292.5MFY2025 · since FY2019: $629.0M → $292.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $292.5M | -30.7% |
| FY2024 | $422.2M | -17.6% |
| FY2023 | $512.2M | -23.2% |
| FY2022 | $666.9M | -27.9% |
| FY2021 | $925.2M | -8.7% |
| FY2020 | $1.0B | +61.1% |
| FY2019 | $629.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice